Deontics Clinical Futures

Deontics successful in NHSX Phase3 AI in Health & Care Awards

Deontics successful in NHSX Phase3 AI in Health & Care Awards

Deontics and consortium members, Guys & St. Thomas’s Hospital, Kings College London, Somerset Cancer Regsiter, Prostate Cancer UK, are pleased to announce their successful application for NHSX Phase III AI in Health & Care Award. At a time when cancer services are increasingly stretched, using Deontics’ unique capabilities to stratify patients and generate personalized, evidence based recommendations, this award will help streamline cancer care for tumor boards and multidisciplinary teams while improving quality and patient involvement in treatment decisions. #AI #clinicaldecisionsupport #cancer #tumorboard #GuysandStThomass #Kingscollegelondon #NHSX #AIinHealthandCareAward #SomersetCancerRegister #ProstateCancerUK #healthtech #oncologyAI in Health & Care Award announcement Sept 2020

Deontics providing diabetes treatment CDS at London Medical

Deontics ( is pleased to announce it has licenced its clinical decision support (CDS) and clinical pathway software to London Medical, a London based private provider of clinical ambulatory care services including endocrinology, cardiovascular, and ophthalmology amongst others.

In the first instance, Deontics will apply its world-leading CDS technology to support and standardise clinical decisions in the treatment of Type I and Type II diabetes, with a view to roll-out in other fields in the future.

Deontics CDS is expected to deliver benefits in streamlining care, automating clinical audit, and patient safety.

Dr. Guy Wood-Gush, CEO Deontics, commented: “We are very pleased to be working with London Medical in the management of their large diabetes practice, and look forward to helping build on their exceptional standards in diabetes and other indications”.

About Deontics
Deontics is a UK based HealthTech spin out from the University of Oxford, Cancer Research UK and University College London. Deontics has a world-leading, CE marked CDS software platform capable of integrating individual patient data with encoded clinical guidelines to dynamically deliver personalised, evidence-based treatment recommendations at the point of care (the “Clinical GPS”). As well as providing CDS, Deontics provides automated clinical audit records and has been shown in published studies to increase compliance with clinical guidelines, reducing unwarranted variation in clinical practice.

About London Medical
London Medical is a leading private outpatient clinic specialising in Diabetes, Endocrinology and related metabolic diseases. For thirty years it has been the leader in introducing new and effective treatments and medicines for diabetes patients from all around the world operating under the brand The London Diabetes Centre. The introduction of Deontics is yet another step to provide exceptional care across all of its specialties.

For more information, please contact:
Dr. Guy Wood-Gush:

Deontics develops first executable Covid 19 clinical pathway

In collaboration with the Royal Liverpool Hospital, Deontics has developed the first executable Covid 19 treatment pathway. This provides evidence-based, personalised, treatment recommendations at the point of care to physicians and nurses treating Covid 19 patients. It is particularly helpful for non-respiratory specialist physicians who are treating such patients, and is a mechanism of delegating expertise and effectively increasing clinical capacity. It also automatically collects epidemiological data, freeing front line clinicians from this task.

The executable Covid 19 treatment pathway was developed very quickly and shows the capability of the Deontics platform to encode clinical logic into a standardised digital logic model to make it executable, editable and deployable.

The Covid 19 treatment pathway, with modifications for local practice, can potentially be used in health systems around the world.

Deontics Acute Coronary Syndrome pathway goes live at Liverpool

Liverpool Go Live announcement

We are pleased to announce that the Deontics Acute Coronary Syndrome clinical pathway has now gone live in the Acute Coronary Care Unit at the Royal Liverpool & Broadgreen University Hospitals NHS Trust.

Dr. Michael Fisher, Chief Clinical Informatics Officer at the RLBUHT, said: “We are delighted to be working with Deontics on this very exciting project and we believe the Deontics CDS platform is one of the best CDS systems available for ensuring clinical quality and efficiency. We will be reviewing progress with a view to potential widespread roll-out throughout the Trust if successful. We anticipate that Deontics can contribute to standardise our care pathways and to reduce costs and increase efficiencies. The goal is to provide the most cost-effective and safest care to our patients and at all times to improve the patient experience and the experience of our staff”.

Pioneering NHS trust using AI to help doctors make right treatment decisions

Royal Liverpool

GDE Trust of the year Royal Liverpool and Broadgreen University Hospitals NHS Trust working with UK-based artificial intelligence health company, Deontics, to enhance clinical decision making and reduce risk of heart attack

London: Global Digital Exemplar, Royal Liverpool and Broadgreen University Hospitals NHS Trust is using artificial intelligence (AI) to improve the treatment of patients who have had a heart attack, in a project that could see wider use of AI to inform treatment decisions across the Trust.

The Trust, which was named as the NHS’ Global Digital Exemplar (GDE) of the year at the 2017 EHI Awards, will use technology from award-winning healthcare firm Deontics. This will enable doctors on the Trust’s acute cardiac unit (ACU) to access AI-driven evidence-based clinical treatment recommendations that are tailored to a patient’s individual needs.

Deontics will encode the appropriate guidelines from the National Institute of Health and Care Excellence (NICE) and other bodies, and make these specific to a patient’s risk factors, which will help doctors avoid medication that could increase risks of bleeding and recurrent heart attack.

“Some of our most frail and elderly patients with acute coronary syndrome are getting some of our most powerful drugs,” says Liverpool chief clinical information officer (CCIO) Mike Fisher.

“Using AI-technology means we should reduce the potential for overprescribing such drugs for patients at lower levels of risk. Instead of giving some patients the maximum treatment, we can make sure patients are given the most appropriate treatment.”

Deontics uses cognitive computing technology and advanced healthcare-specific logic to act like a ‘clinical sat-nav’ for doctors. This enables them to make treatment decisions that are dynamically informed by relevant standards and guidelines such as those issued by NICE, and the latest good practice from published papers and reputable sources. These are then applied directly to the precise needs of individual patients according to their condition.

Expected benefits include greater clinical compliance with standards, leading to increased care quality, enhanced patient outcomes, and reduced length of stay. Such compliance is a major driver for the NHS through activities such as its “Getting It Right First Time” programme and following recommendations from Lord Carter’s report into NHS productivity.

“There is much evidence to show that the most effective hospitals are those that follow guideline-based treatments more closely,” said Fisher, which is using Deontics as part of the trust’s Digital Liverpool initiative. Deontics will help the Trust achieve greater compliance with those standards, and record any justified variation from the treatment recommended in accepted guidelines.

Deontics is to be used on the Royal’s ACU over Summer 2018, initially linking to the Trust’s electronic notes system, with a view to integrating with other key clinical systems, including the forthcoming electronic patient record system. Then, once a patient is given a diagnosis of acute coronary syndrome, the decision support system will present personalised evidence on relevant treatment options and the best clinical pathway to use. Doctors can then follow that advice, or record why they provided alternative treatment.

Once it proves itself in the ACU, Deontics could be used across the hospital in support of its Advancing Quality programme, which looks to provide high quality care for a range of high impact conditions such as heart failure. “We aim to start within something relatively simple, and then build up from there,” said the CCIO.

“Deontics is one of the smartest decision support systems out there,” said Fisher. “It has been used to individually recommend different chemotherapy regimes based on complex research. No other system can do this. It is a very interesting firm, and we are hopeful for a continued relationship.”

Guy Wood-Gush, CEO of Deontics, said: “It is very exciting to be working with the Trust on realising the possibilities of using AI to enhance clinical treatment decisions using Deontics technology. We have spent many years working with clinicians to develop a platform that fits with their needs and workflow. We have shown how our healthcare AI technology can increase patient safety, reduce unnecessary clinical variation, and deliver high quality, cost-effective care and we look forward to bringing these benefits to patients in Liverpool.”

Deontics technology is the result of long-term academic research in medical artificial intelligence. Its innovative software has helped it win the London Mayor’s MedTech business award, and seen it shortlisted for this year’s Patient Safety Awards. Deontics is also only one of seven companies worldwide named in Gartner’s “Cool Vendors in AI in Healthcare” report in 2017.

Editor’s notes

Media contacts

Becky Mellor, Highland Marketing (on behalf of Deontics)

Tel: +44 (0) 1877 332714


Rob Benson, Highland Marketing (on behalf of Deontics)

Tel: +44 (0) 1877 332722


About Deontics

Deontics provides personalised clinical decision support software that is the result of long-term academic research in medical artificial intelligence (AI) originating at Carnegie Mellon University, and subsequently developed at the Medical Research Council, University of Oxford, University College London and Cancer Research UK.

Deontics was founded to incorporate concepts rooted in cognitive science, AI and medical informatics into day-to-day clinical decision making in order to improve the quality of medical care in the UK and throughout the world. Deontics provides clinically-led artificial intelligence for healthcare providers, payers and patients that delivers personalised clinical decision support for quality patient outcomes. A clinical ‘sat nav’ for personalised care, it dynamically integrates clinical good practice at national and local level with individual patient information directly into the patient pathway.

Enabling sophisticated and detailed clinical audit, use of Deontics systems throughout a network of hospitals and primary care clinicians can greatly enhance the quality of integrated care as well as the quality of individual specific clinical decisions. To find out more about Deontics, visit

About the Royal Liverpool and Broadgreen University Hospitals NHS Trust
The Royal Liverpool and Broadgreen University Hospitals NHS Trust is one of the largest and busiest acute hospital trusts in the North of England, with an annual budget exceeding £40m.  It delivers services across two sites and three hospitals, the Royal Liverpool University Hospital, Broadgreen Hospital and Liverpool University Dental Hospital, and employs approximately 7,600 people. It provides a comprehensive range of specialist services to 750,000 people each year within a total catchment population of more than two million people in Merseyside, Cheshire, North Wales, the Isle of Man and beyond.

The Trust provides general hospital services to the adult population of Liverpool and the Royal Liverpool Hospital has one of the busiest emergency departments in the North West, providing care and treatment for patients who have life threatening injuries and serious illnesses, such as strokes and heart attacks. It is a major centre for the diagnosis, treatment, care and research of cancer, as well as a regional cancer centre for pancreatic, urological, ocular, testicular, and oesophago-gastric cancers, specialist palliative care, specialist radiology and specialist pathology and chemotherapy cancer treatment services.

It is one of the top teaching trusts in the UK with well-established links to the University of Liverpool, Liverpool John Moores University and international institutions. A new £335m state of the art Royal Liverpool University Hospital is currently in development.

To find out more about the Trust, visit